Cargando…
Extracorporeal Membrane Oxygenation in Nivolumab Associated Pneumonitis
BACKGROUND: Newly approved immunotherapeutic agents, like CTLA-4 inhibitors and antibodies against PD-1, are a promising therapeutic option in cancer therapy. CASE PRESENTATION: A 74-year-old man, with a history of advanced stage melanoma and treatment with ipilimumab, pembrolizumab and nivolumab, w...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
De Gruyter Open
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769916/ https://www.ncbi.nlm.nih.gov/pubmed/29967877 http://dx.doi.org/10.1515/jccm-2017-0013 |